Amgen To Present New Data From The Repatha ® (Evolocumab) Cardiovascular Outcomes Study At ESC Congress 2017

Analysis Evaluates the Effect of Repatha in More Than 5,000 Patients With a History of Stroke THOUSAND OAKS, Calif., Aug. 21, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from the Repatha® (evolocumab) clinical trial program, including three late-breaking scientific sessions, will be presented at the European Society of Cardiology (ESC) Congress 2017 in Barcelona, Spain, Aug. 26-30, 2017. New data includes additional efficacy and safety analyses from the Repatha cardiovascular outcomes trial (FOURIER) and the Repatha coronary intravascular ultrasound imaging trial (GLAGOV). "Data from the Repatha clinical trial program continue to reinforce the value of this...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news